ReviewFrontiers in oncology2024

Nanoparticle-enhanced PD-1/PD-L1 targeted combination therapy for triple negative breast cancer.

Caroline Linde et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.